Clinical Drug Investigation

, Volume 17, Issue 2, pp 137–144

Oral Sumatriptan Pharmacokinetics in the Migraine State

  • John J. Sramek
  • Elizabeth K. Hussey
  • Bill Clements
  • Neal R. Cutler
Clinical Pharmacokinetics


Objective: This double-blind, parallel, multicentre study investigated the effect of migraine on absorption of oral sumatriptan (25, 50 and 100mg) compared with placebo.

Design: Patients received sumatriptan or placebo in the clinic during an acute migraine and at least 7 days later, when pain-free. Pharmacokinetic and efficacy (n = 192) and safety (n = 259) parameters were assessed for 4 hours after administration of study medication.

Results: Absorption of sumatriptan from 50 and 100mg tablets was not significantly different between the migraine and pain-free periods. There was however a statistically significant decrease (approximately 23%) and delay (35 minutes) in absorption of sumatriptan from the 25mg tablet during a migraine compared with the pain-free period. Sumatriptan pharmacokinetics exhibited dose proportionality during the migraine and pain-free periods. All doses of sumatriptan were significantly superior to placebo in reducing headache pain. Adverse events were comparable among the sumatriptan groups and placebo group.

Conclusions: Absorption of sumatriptan, administered at therapeutic doses, was not statistically significantly impaired during migraine versus the pain-free state. These data suggest that coadministration of drugs that improve the absorption of sumatriptan is not necessary during sumatriptan treatment.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Connor HE, Feniuk W, Humphrey PPA. Characterization of 5-HT receptors mediating contraction of canine and primate basilar artery by use of GR43175, a selective 5-HT1-like receptor agonist. Br J Pharmacol 1989; 96: 379–87PubMedCrossRefGoogle Scholar
  2. 2.
    Humphrey PPA, Feniuk W, Perren MJ, et al. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia 1989; 9 Suppl. 9: 23–33PubMedGoogle Scholar
  3. 3.
    Parsons AA, Whalley ET. Characterization of the 5-hydroxy-tryptamine receptor which mediates contraction of the human isolated basilar artery. Cephalalgia 1989; 9 Suppl. 9: 47–51PubMedGoogle Scholar
  4. 4.
    Van Es NM, Bruning TA, Camps J, et al. Assessment of peripheral vascular effects of antimigraine drugs in humans. Cephalalgia 1995; 15(4): 288–91CrossRefGoogle Scholar
  5. 5.
    Dechant KL, Clissold SP. Sumatriptan: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992; 43(5): 776–98PubMedCrossRefGoogle Scholar
  6. 6.
    Scott AK. Sumatriptan: clinical pharmacokinetics. Clin Pharmacokinet 1994; 27: 337–44PubMedCrossRefGoogle Scholar
  7. 7.
    Friberg L, Olesen J, Iversen HK, et al. Migraine pain associated with middle cerebral artery dilation: reversal by sumatriptan. Lancet 1991; 338: 13–7PubMedCrossRefGoogle Scholar
  8. 8.
    Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992; 13:307–12PubMedCrossRefGoogle Scholar
  9. 9.
    Goadsby PJ, Hoskin KL. Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5HT1b/1d receptor: a central action in migraine? Ann Neurol 1998; 43(6): 711–8PubMedCrossRefGoogle Scholar
  10. 10.
    Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99: 202–6PubMedCrossRefGoogle Scholar
  11. 11.
    Pearce JMS. Sumatriptan: efficacy and contribution to migraine mechanisms. J Neurol Neurosurg Psychiatry 1992; 55: 1103–5PubMedCrossRefGoogle Scholar
  12. 12.
    Plosker GL, McTavish D. Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994; 47(4): 622–51PubMedCrossRefGoogle Scholar
  13. 13.
    May A, Shepheard SL, Knorr M, et al. Retinal plasma extravasation in animals but not humans: implications for the pathophysiology of migraine. Brain 1998; 121: 1231–7PubMedCrossRefGoogle Scholar
  14. 14.
    Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265: 2831–5PubMedCrossRefGoogle Scholar
  15. 15.
    The Oral Sumatriptan Dose-Defining Study Group. Sumatriptan — an oral dose defining study. Eur Neurol 1991; 31: 300–5CrossRefGoogle Scholar
  16. 16.
    Carpay HA, Matthijsse P, Steinbuch M, et al. Oral and subcutaneous sumatriptan in the acute treatment of migraine: an open randomized cross-over study. Cephalalgia 1997; 17(5): 591–5PubMedCrossRefGoogle Scholar
  17. 17.
    Kelly AM, Ardagh M, Curry C, et al. Intravenous chlorpromazine versus intramuscular sumatriptan for acute migraine. J Accid Emerg Med 1997; 14(4): 209–11PubMedCrossRefGoogle Scholar
  18. 18.
    Eckborn K, Monstad I, Prusinski A, et al. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. Acta Neurol Scand 1993; 88: 63–9Google Scholar
  19. 19.
    Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology 1997; 49(5): 1225–30PubMedCrossRefGoogle Scholar
  20. 20.
    Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs 1998; 55(6): 889–922PubMedCrossRefGoogle Scholar
  21. 21.
    Boyle R, Behan PO, Sutton JA. Acorrelation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br J Clin Pharmacol 1990; 30: 405–9PubMedCrossRefGoogle Scholar
  22. 22.
    Volans GN. Research review — Migraine and drug absorption. Clin Pharmacokinet 1978; 3: 313–8PubMedCrossRefGoogle Scholar
  23. 23.
    Ross-Lee LM, Eadie MJ, Heazlewood V, et al. Aspirin pharmacokinetics in migraine. The effect of metoclopramide. Eur J Clin Pharmacol 1983; 24: 777–85PubMedCrossRefGoogle Scholar
  24. 24.
    Tokola RA, Neuvonen PJ. Effect of migraine attacks on paracetamol absorption. Br J Clin Pharmacol 1984; 18: 867–71PubMedCrossRefGoogle Scholar
  25. 25.
    Tokola RA. The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine. Cephalalgia 1988; 8: 139–47PubMedCrossRefGoogle Scholar
  26. 26.
    Tokola RA, Neuvonen PJ. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol 1984; 17: 67–75PubMedCrossRefGoogle Scholar
  27. 27.
    Pini LA, Bertolotti M, Trenti T, et al. Disposition of naproxen after oral administration during and between migraine attacks. Headache 1993; 33(4): 191–4PubMedCrossRefGoogle Scholar
  28. 28.
    Houghton LA, Fowler P, Keene ON, et al. Effect of sumatriptan, a new selective 5HT-1-like agonist, on gastric emptying in man. Aliment Pharmacol Ther 1992; 6(6): 685–91PubMedCrossRefGoogle Scholar
  29. 29.
    Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 19–28Google Scholar
  30. 30.
    Busch MA, Plachetka JR, Donn KH, et al. Evaluation of the pharmacokinetics and safety of ascending single oral doses of GR43175 administered to healthy male volunteers. Cephalalgia 1989; 9 Suppl. 10: 414–5Google Scholar
  31. 31.
    Pini L-A, Bertolotti M, Bergonzini G, et al. Pharmacokinetics of tiaprofenic acid after oral administration in fasting patients during and between migraine attacks. Headache 1990; 30: 672–5PubMedCrossRefGoogle Scholar
  32. 32.
    Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291–4PubMedCrossRefGoogle Scholar
  33. 33.
    Fowler PA, Lacey LF. The effect of food on the pharmacokinetic profile of sumatriptan. Abstract XVth World Congress of Neurology, Vancouver, September 5–10, 1993Google Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • John J. Sramek
    • 1
  • Elizabeth K. Hussey
    • 2
  • Bill Clements
    • 2
  • Neal R. Cutler
    • 1
  1. 1.California Clinical TrialsBeverly HillsUSA
  2. 2.Glaxo Research InstituteResearch Triangle ParkUSA

Personalised recommendations